# ‚öîÔ∏è QUARTERLY GOALS - Q4 2025 & Q1 2026

**Last Updated:** November 15, 2025

---

## üéØ Q4 2025 (OCT-DEC 2025)

### **Objective 1: Complete Metastasis V1 Publication**

**Key Results:**
- ‚úÖ **Week 1 Validation Complete** (Target-Lock AUROC 0.976, n=38 genes)
- üîÑ **Week 2 Structural Validation** (AlphaFold real guides, Boltz fast-mode)
  - [ ] Real guide JSONs tested on AlphaFold Server (15 guides, pLDDT >70)
  - [ ] Boltz fast-mode operational (pLDDT 67.09 baseline achieved)
  - [ ] Structural validation figures generated
- [ ] **Manuscript Draft Complete** (Abstract, Methods, Results, Discussion)
- [ ] **Figures Publication-Ready** (8-step cascade, Target-Lock heatmap, guide validation)
- [ ] **Supplementary Materials Complete** (Tables, extended methods)

**Timeline:**
- Week 2 complete: November 22, 2025
- Manuscript draft: December 6, 2025
- Internal review: December 13, 2025
- Final revisions: December 20, 2025

---

### **Objective 2: Close First Partnership (BriaCell)**

**Key Results:**
- ‚úÖ **Cold Email Drafted & Corrected** (no hallucinations)
- ‚úÖ **1-Pager Corrected** (General1Page_CORRECTED.tsx - bulletproof)
- [ ] **Cold Email Sent** (with PDF attachment)
- [ ] **Discovery Call Scheduled** (20-min call)
- [ ] **Free Pilot Proposal Presented** (20-patient retrospective)
- [ ] **Pilot Agreement Signed** (free or $250K paid pilot)

**Timeline:**
- Email sent: November 18, 2025
- Follow-up Day 3: November 21, 2025
- Discovery call target: November 25-29, 2025
- Proposal sent: December 2, 2025
- Agreement target: December 20, 2025

**Pipeline Value (If Successful):**
- Free pilot: $0 upfront, proof-of-concept for case study
- Paid pilot: $250K (6 weeks, 50-100 patients)

---

### **Objective 3: Build Lead Gen Infrastructure (Agent X)**

**Key Results:**
- ‚úÖ **Lead Gen System Doctrine Complete** (1053 lines, execution plan)
- ‚úÖ **Command Center Structure Operational** (7-tier hierarchy)
- [ ] **Phase 1: Data Acquisition** (500+ trials, 200+ grants, 100+ ASCO abstracts)
- [ ] **Phase 2: Data Enrichment** (Master lead list, H-index scoring, talking points)
- [ ] **Phase 3: Email Automation** (Templates, sending infrastructure)
- [ ] **Phase 4: Tracking & Follow-Up** (Dashboard, response tracking)

**Timeline:**
- Phase 1 complete: November 29, 2025
- Phase 2 complete: December 13, 2025
- Phase 3 complete: December 27, 2025
- Phase 4 complete: January 10, 2026
- **LAUNCH GATED UNTIL Q1 2026** (publication submission)

---

## üéØ Q1 2026 (JAN-MAR 2026)

### **Objective 1: Submit Metastasis V1 to Nature Biotechnology**

**Key Results:**
- [ ] **Manuscript Submitted** (Nature Biotechnology, Q1 2026 target)
- [ ] **Preprint Posted** (bioRxiv)
- [ ] **ASCO 2026 Abstract Submitted** (Deadline: November 30, 2025)

**Timeline:**
- Submission: January 10, 2026
- Preprint: January 15, 2026
- ASCO abstract: November 30, 2025 (Q4 2025 carryover)

---

### **Objective 2: Launch Mass Outreach Campaign**

**Key Results:**
- [ ] **Tier 1 Emails Sent** (100 PIs, highest priority)
- [ ] **Tier 2 Emails Sent** (200 PIs, moderate priority)
- [ ] **Response Rate ‚â•10%** (Tier 1)
- [ ] **20-30 Discovery Calls Scheduled**
- [ ] **5-14 Pilots Signed** (conversion rate 20-30%)

**Timeline:**
- Tier 1 launch: January 13, 2026 (Week 1 after submission)
- Tier 2 launch: January 20, 2026 (Week 2)
- Tier 3 launch: January 27, 2026 (Week 3)
- Response analysis: February 3, 2026 (Week 4)

**Pipeline Value (If Successful):**
- 5-14 pilots @ $250K = $1.25M - $3.5M pipeline
- Expected close rate: 50% = $625K - $1.75M revenue

---

### **Objective 3: Scale Partnerships (2-5 Active Deals)**

**Key Results:**
- [x] **BriaCell** (Q4 2025 carryover - pilot in progress)
- [ ] **MD Anderson** (TLS/TCF1 collaboration)
- [ ] **MSK** (TLS collaboration)
- [ ] **NCI Cooperative Group** (1 group = 200+ trial sites)
- [ ] **Big Pharma** (Merck/BMS/Roche - pipeline stratification)

**Pipeline Value:**
- BriaCell: $250K (pilot) ‚Üí $1-5M (platform license)
- MD Anderson: Free collaboration ‚Üí co-publication ‚Üí grants
- MSK: Free collaboration ‚Üí co-publication ‚Üí grants
- NCI Group: $500K - $2M (multi-trial stratification)
- Big Pharma: $1-5M (platform license)

---

## üìä SUCCESS METRICS (Q1 2026 END)

| Metric | Target | Status |
|--------|--------|--------|
| **Publication Submitted** | Yes (Nature Biotech) | Pending |
| **ASCO 2026 Abstract Accepted** | Yes | Pending (submit Nov 30) |
| **Partnerships Active** | 2-5 | 1 (BriaCell) |
| **Discovery Calls Completed** | 20-30 | 0 |
| **Pilots Signed** | 5-14 | 0 |
| **Revenue Pipeline** | $1.25M - $3.5M | $0 (BriaCell pending) |
| **Closed Revenue** | $250K - $1M | $0 |

---

## üîÑ QUARTERLY REVIEW PROCESS

### **Monthly Review (1 hour):**
- What worked this month?
- What didn't work?
- Blockers encountered?
- Adjustments needed?

### **Quarterly Review (2 hours):**
- Did we hit our OKRs?
- What was the biggest win?
- What was the biggest failure?
- What do we do differently next quarter?

---

**‚öîÔ∏è STAY FOCUSED. EXECUTE RELENTLESSLY. MEASURE RUTHLESSLY.**

